Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Clinical and genetic risk factors for epirubicin-induced cardiac toxicity in early breast cancer patients
Christof Vulsteke, Alena M. Pfeil, Charlotte Maggen, et al.
Breast Cancer Research and Treatment (2015) Vol. 152, Iss. 1, pp. 67-76
Closed Access | Times Cited: 70

Showing 1-25 of 70 citing articles:

ABC Family Transporters
Xiaodong Liu
Advances in experimental medicine and biology (2019), pp. 13-100
Closed Access | Times Cited: 212
Recommendations for genetic testing to reduce the incidence of anthracycline‐induced cardiotoxicity
Folefac Aminkeng, Colin J.D. Ross, Shahrad R. Rassekh, et al.
British Journal of Clinical Pharmacology (2016) Vol. 82, Iss. 3, pp. 683-695
Open Access | Times Cited: 210
SLC Family Transporters
Xiaodong Liu
Advances in experimental medicine and biology (2019), pp. 101-202
Closed Access | Times Cited: 198
Novel genetic and epigenetic factors of importance for inter-individual differences in drug disposition, response and toxicity
Volker M. Lauschke, Yitian Zhou, Magnus Ingelman‐Sundberg
Pharmacology & Therapeutics (2019) Vol. 197, pp. 122-152
Open Access | Times Cited: 113
Candidate Gene Association Studies of Anthracycline-induced Cardiotoxicity: A Systematic Review and Meta-analysis
Siew Lian Leong, Nathorn Chaiyakunapruk, Shaun Wen Huey Lee
Scientific Reports (2017) Vol. 7, Iss. 1
Open Access | Times Cited: 92
An update of the molecular mechanisms underlying anthracycline induced cardiotoxicity
Sicong Xie, Yuwei Sun, Xuan Zhao, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 8
Chemotherapy-Related Cardiac Dysfunction
Marijke Linschoten, Arco J. Teske, Maarten J. Cramer, et al.
Circulation Genomic and Precision Medicine (2018) Vol. 11, Iss. 1
Open Access | Times Cited: 78
Genetics of Anthracycline Cardiomyopathy in Cancer Survivors
Smita Bhatia
JACC CardioOncology (2020) Vol. 2, Iss. 4, pp. 539-552
Open Access | Times Cited: 66
Molecular mechanisms of anthracycline cardiovascular toxicity
Anna Narezkina, Hari K. Narayan, Alice E. Zemljic‐Harpf
Clinical Science (2021) Vol. 135, Iss. 10, pp. 1311-1332
Closed Access | Times Cited: 43
Artificial intelligence electrocardiogram as a novel screening tool to detect a newly abnormal left ventricular ejection fraction after anthracycline-based cancer therapy
J. Jacobs, Grace Greason, Kathryn Mangold, et al.
European Journal of Preventive Cardiology (2023) Vol. 31, Iss. 5, pp. 560-566
Open Access | Times Cited: 20
Serum biomarkers evaluation to predict chemotherapy-induced cardiotoxicity in breast cancer patients
Francesca De Iuliis, Gerardo Salerno, Ludovica Taglieri, et al.
Tumor Biology (2015) Vol. 37, Iss. 3, pp. 3379-3387
Closed Access | Times Cited: 63
Adjuvant breast cancer treatments cardiotoxicity and modern methods of detection and prevention of cardiac complications
Agata Bikiewicz, Maciej Banach, Stephan von Haehling, et al.
ESC Heart Failure (2021) Vol. 8, Iss. 4, pp. 2397-2418
Open Access | Times Cited: 34
Possible roles of genetic variations in chemotherapy related cardiotoxicity in pediatric acute lymphoblastic leukemia and osteosarcoma
Judit C. Sági, Bálint Egyed, Andrea Kelemen, et al.
BMC Cancer (2018) Vol. 18, Iss. 1
Open Access | Times Cited: 41
Heart Failure in Relation to Anthracyclines and Other Chemotherapies
Tolulope A. Agunbiade, Raja Zaghlol, Ana Barac
Methodist DeBakey Cardiovascular Journal (2019) Vol. 15, Iss. 4, pp. 243-243
Open Access | Times Cited: 37
Toxicity and Pharmacogenomic Biomarkers in Breast Cancer Chemotherapy
Zeina N. Al-Mahayri, George P. Patrinos, Bassam R. Ali
Frontiers in Pharmacology (2020) Vol. 11
Open Access | Times Cited: 37
Risk prediction model for long-term heart failure incidence after epirubicin chemotherapy for breast cancer – A real-world data-based, nationwide classification analysis
György Fogarassy, Ágnes Vathy-Fogarassy, István Kenessey, et al.
International Journal of Cardiology (2019) Vol. 285, pp. 47-52
Closed Access | Times Cited: 36
Genetics of cancer therapy-associated cardiotoxicity
Yuri Kim, Jonathan G. Seidman, Christine E. Seidman
Journal of Molecular and Cellular Cardiology (2022) Vol. 167, pp. 85-91
Open Access | Times Cited: 19
Genetic Background in Patients with Cancer Therapy-Induced Cardiomyopathy
Luca Fazzini, N Campana, Stefano Cossu, et al.
Journal of Clinical Medicine (2025) Vol. 14, Iss. 4, pp. 1286-1286
Open Access
SNP’s use as a potential chemotoxicity stratification tool in breast cancer: from bench to clinic
Hebatallah Ahmed Mohamed Moustafa, Walaa A. El‐Dakroury, Alaa Ashraf, et al.
Functional & Integrative Genomics (2025) Vol. 25, Iss. 1
Closed Access
Pharmacogenomics in drug-induced cardiotoxicity: Current status and the future
Moyun Li, Peng Li-ming, Xiaoping Chen
Frontiers in Cardiovascular Medicine (2022) Vol. 9
Open Access | Times Cited: 17
A Precision Medicine Approach to Improve Cancer Rehabilitation’s Impact and Integration with Cancer Care and Optimize Patient Wellness
Catherine M. Alfano, David S. Zucker, Mackenzi Pergolotti, et al.
Current Physical Medicine and Rehabilitation Reports (2017) Vol. 5, Iss. 1, pp. 64-73
Closed Access | Times Cited: 29
New Insights in the Era of Clinical Biomarkers as Potential Predictors of Systemic Therapy-Induced Cardiotoxicity in Women with Breast Cancer: A Systematic Review
Alexia Alexandraki, Elisavet Papageorgiou, Marina Zacharia, et al.
Cancers (2023) Vol. 15, Iss. 13, pp. 3290-3290
Open Access | Times Cited: 8
Exome array analysis identifies ETFB as a novel susceptibility gene for anthracycline-induced cardiotoxicity in cancer patients
Sara Ruiz‐Pinto, Guillermo Pita, Miguel Martín, et al.
Breast Cancer Research and Treatment (2017) Vol. 167, Iss. 1, pp. 249-256
Open Access | Times Cited: 26
hiPSCs in cardio-oncology: deciphering the genomics
Emily Pinheiro, K. Ashley Fetterman, Paul W. Burridge
Cardiovascular Research (2019) Vol. 115, Iss. 5, pp. 935-948
Open Access | Times Cited: 24
Pharmacogenomics in Pediatric Oncology: Mitigating Adverse Drug Reactions While Preserving Efficacy
Abdelbaset Elzagallaai, Bruce Carleton, Michael Rieder
The Annual Review of Pharmacology and Toxicology (2020) Vol. 61, Iss. 1, pp. 679-699
Closed Access | Times Cited: 22
Page 1 - Next Page

Scroll to top